Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AS703569 + gemcitabine
- Development stage
- Phase 1
- Lead developer
- Merck KGaA
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
AS703569 + gemcitabine is an investigational combination therapy for cancer. AS703569 (also known as R763) is a highly potent, orally available small molecule inhibitor of Aurora kinase A and Aurora kinase B, as well as several other kinases. Aurora kinases are critical regulators of mitosis and are implicated in tumorigenesis; their inhibition disrupts cell division and induces apoptosis in cancer cells[6][8]. Gemcitabine is a nucleoside analog antimetabolite chemotherapeutic agent that inhibits DNA synthesis by incorporating into DNA during replication, leading to cell cycle arrest and apoptosis[4]. Gemcitabine is approved for use in various cancers including pancreatic, ovarian, breast, and non-small cell lung cancer[1][3][4]. The combination has been studied in early-phase clinical trials for advanced malignancies such as pancreatic, ovarian, breast, non-small cell lung cancer (NSCLC), and colorectal cancers[8].
- Brand names
- Gemzar
02
Targets
AURKA (Aurora kinase A)AURKB (Aurora kinase B)DNA polymerase familyRNR (Ribonucleotide reductase)
Beyond the preview
Go deeper on AS703569 + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AS703569 + gemcitabine.